MedPath

HLA-G Immuno-Inhibitor Checkpoint Study in Patients With COVID-19 Infection: Molecular and Cellular Assessment

Not Applicable
Completed
Conditions
Covid19
Interventions
Other: Baseline blood sample
Other: Baseline and during hospitalization blood samples
Registration Number
NCT04613297
Lead Sponsor
Hopital Foch
Brief Summary

The aim of the research is to study the immune checkpoint linked to the HLA-G molecule in the dysregulation of the control of COVID-19 infection.

Detailed Description

Single-center, prospective, open-ended, interventional study with minimal risks and constraints. Patients will be divided into 3 groups: patients not infected with COVID-19, patients infected with COVID-19 not hospitalized, patients infected with COVID-19 hospitalized.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
91
Inclusion Criteria
  • Patient with possible or confirmed infection by COVID-19
Read More
Exclusion Criteria
  • Patient without liberty or guardianship
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
COVID-19 uninfected patientsBaseline blood samplePatient with negative PCR result
non-hospitalized COVID-19 infected patientsBaseline blood samplePatient with positive PCR result who does not require hospitalization for COVID-19
hospitalized COVID-19 infected patientsBaseline and during hospitalization blood samplesPatient with positive PCR who require hospitalization for COVID-19
Primary Outcome Measures
NameTimeMethod
Comparison of the percentage of T cells expressing the HLA-G receptor ILT2 (CD3+CD4+ILT2+ T cells, and CD3+CD8+ILT2+ T cells) between the 3 groups of patients.1 month

The CD3 + T lymphocyte cell populations (CD4 + ILT2 + and CD8 + ILT2 +) will be compared between the groups of patients

Comparison of the expression of circulating soluble HLA-G, between the groups of patients.1 day

Blood levels of soluble HLA-G and plasma microvesicles with expression of HLA-G will be compared between the groups of patients.

Secondary Outcome Measures
NameTimeMethod
1 month survival1 month

Vital status collected 1 month post inclusion for all the patients

Comparison of the expression of one of the cell receptors of the SARS-CoV-2 virus, called BSG (Basigin), whose expression is modified by the interaction between HLA-G.1 day

The expression of the BSG cell receptor induced by HLA-G will be compared between COVID19 patients and uninfected patients.

Assessment of the severity of the disease according to the isoform of HLA-G1 month

Comparison of the isoforms (alleles) of HLA-G regarding the severity of the disease for the infected patients.

Trial Locations

Locations (1)

Foch hospital

🇫🇷

Suresnes, France

© Copyright 2025. All Rights Reserved by MedPath